These transgenic mice express the reverse tetracycline-controlled transactivator (rtTA) protein under the control of the rat Scgb1a1, secretoglobin, family 1A, member 1 (uteroglobin), gene promoter. In situ hybridization detects rtTA mRNA in bronchial and type II epithelial cells of lung tissue from adult transgenic mice treated with doxycycline for seven days. Induction of transgene expression is detected as early as postconception day 14 when the pregnant female is treated with doxycycline. When mated to a second transgenic strain carrying a gene under the regulatory control of a tetracycline-responsive promoter element (tetO), expression of the gene can be regulated by the tetracycline analog, doxycycline (dox); in the presence of dox, transcription of the target gene is induced in cells where rtTA is expressed. Mice hemizygous for the CCSP-rtTA transgene are viable, fertile, normal in size, and do not display any gross physical or behavioral abnormalities.
This founder line has less non-doxycycline-dependent expression of rtTA than Founder Line 1 (See Stock No. 006232, and Stock No. 006242)
